Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 3/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 7/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404747 | 1.00 | PDE7A (0.43) | PDE7ADAOMEN1KMT2ACYP1A2 | |
| SCHEMBL22552200 | 0.69 | NOX4 (0.42) | MEN1KMT2ACYP1A2MAPTHPGD | |
| SCHEMBL29480971 | 0.68 | MAPK14 (0.45) | PDE7ADHODH | |
| SCHEMBL22552408 | 0.66 | DHODH (0.67) | PDE7AMEN1KMT2AHPGDDHODH | |
| SCHEMBL29403737 | 0.66 | DHODH (0.67) | PDE7AMEN1KMT2AHPGDDHODH | |
| SCHEMBL30319354 | 0.65 | KDM4E (0.55) | DAONOX4 | |
| SCHEMBL17543221 | 0.60 | PDE7A (0.38) | PDE7ADAOMEN1KMT2AMAPT | |
| SCHEMBL18239982 | 0.60 | PDE7A (1.00) | PDE7AMAPT | |
| SCHEMBL16332881 | 0.60 | ALDH1A1 (0.38) | PDE7AKMT2ACYP1A2HPGDCYP2C19 | |
| SCHEMBL5591627 | 0.59 | ALDH1A1 (0.40) | MEN1KMT2AMAPTNOX4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956320-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2023-09-12 | — | — | US | disclosed |
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | JANSSEN BIOTECH, INC. | 2022-11-22 | — | — | US | disclosed |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH INC (US) | 2022-09-22 | — | — | US | disclosed |
| CN-114174278-A | Dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3956320-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | Janssen Biotech, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2020-10-22 | — | — | US | disclosed |
| WO-2020212897-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753393-B2 | Dihydroorotate dehydrogenase inhibitors | DHODH, DLD, DPYD | PDE7A 1663/4885DAO 212/4885MEN1 3056/4885 |
| US-11505536-B2 | Dihydroorotate dehydrogenase inhibitors | DHODH, DLD, DPYD | PDE7A 1663/4885DAO 212/4885MEN1 3056/4885 |
| US-20220298137-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | PDE7A 1663/4885DAO 212/4885MEN1 3056/4885 |
| US-20200331881-A1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DLD, DPYD | PDE7A 1663/4885DAO 212/4885MEN1 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.